Results 1 to 10 of about 9,417 (98)

Evaluating the efficacy of ceftazidime/avibactam plus amikacin combination therapy as a carbapenem-sparing agent against ceftazidime/avibactam-resistant Escherichia coli using a hollow fiber infection model: a proof-of-concept study [PDF]

Antimicrobial Agents and Chemotherapy
Carbapenems, often regarded as the last line of defense in treatment of urinary tract infections and urosepsis caused by Escherichia coli, are under pressure from emerging resistance.
Mikaela M. Walker, Jason A. Roberts, Yixuan Li, Saiyuri Naicker, Steven C. Wallis, Jenny L. Ordonez, Hayoung Won, Brian M. Forde, Fekade B. Sime   +8 more
doaj   +2 more sources

In vitro Optimization of Ceftazidime/Avibactam for KPC-Producing Klebsiella pneumoniae

Frontiers in Microbiology, 2021
Ceftazidime/avibactam is an important treatment option for infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae (KPC-Kp), however, resistance can emerge during treatment.
Yanqin Huang, Tiffany Wu, Omar Perez, Amisha P. Rana, Liang Chen, Liang Chen, Barry N. Kreiswirth, Michael J. Satlin, Zackery P. Bulman   +8 more
doaj   +1 more source

Ceftazidime-Avibactam Therapy Versus Ceftazidime-Avibactam-Based Combination Therapy in Patients With Carbapenem-Resistant Gram-Negative Pathogens: A Meta-Analysis

Frontiers in Pharmacology, 2021
Objective: To systematically review and compare the efficacy and posttreatment resistance of ceftazidime-avibactam therapy and ceftazidime-avibactam-based combination therapy in patients with Gram-negative pathogens.Methods: PubMed, Embase, Web of ...
Dan Li, Dan Li, Dan Li, Fan Fei, Hua Yu, Xiangning Huang, Shanshan Long, Hao Zhou, Jie Zhang   +8 more
doaj   +1 more source

In Vitro Activities of Ceftazidime–Avibactam and Aztreonam–Avibactam at Different Inoculum Sizes of Extended-Spectrum β-Lactam-Resistant Enterobacterales Blood Isolates

Antibiotics, 2021
β-lactam–avibactam combinations have been proposed as carbapenem-sparing therapies, but little data exist on their in vitro activities in infections with high bacterial inocula.
Moonsuk Bae, Taeeun Kim, Joung Ha Park, Seongman Bae, Heungsup Sung, Mi-Na Kim, Jiwon Jung, Min Jae Kim, Sung-Han Kim, Sang-Oh Lee, Sang-Ho Choi, Yang Soo Kim, Yong Pil Chong   +12 more
doaj   +1 more source

In-Vitro Selection of Ceftazidime/Avibactam Resistance in OXA-48-Like-Expressing Klebsiella pneumoniae: In-Vitro and In-Vivo Fitness, Genetic Basis and Activities of β-Lactam Plus Novel β-Lactamase Inhibitor or β-Lactam Enhancer Combinations

Antibiotics, 2021
Ceftazidime/avibactam uniquely demonstrates activity against both KPC and OXA-48-like carbapenemase-expressing Enterobacterales. Clinical resistance to ceftazidime/avibactam in KPC-producers was foreseen in in-vitro resistance studies.
Snehal Palwe, Yamuna Devi Bakthavatchalam, Kshama Khobragadea, Arun S. Kharat, Kamini Walia, Balaji Veeraraghavan   +5 more
doaj   +1 more source

Increased gene expression and copy number of mutated bla KPC lead to high-level ceftazidime/avibactam resistance in Klebsiella pneumoniae

BMC Microbiology, 2021
Background Resistance to ceftazidime-avibactam was reported, and it is important to investigate the mechanisms of ceftazidime/avibactam resistance in K. pneumoniae with mutations in bla KPC. Results We report the mutated bla KPC is not the only mechanism
Lingxiao Sun, Haibo Li, Qi Wang, Yingmei Liu, Bin Cao   +4 more
doaj   +1 more source

Effectiveness of ceftazidime–avibactam versus colistin in treating carbapenem-resistant Enterobacteriaceae bacteremia

International Journal of Infectious Diseases, 2021
Introduction: Antimicrobial treatments for carbapenem-resistant Enterobacteriaceae (CRE) bacteremia are limited, with colistin-based regimens being a primary therapy. Ceftazidime–avibactam is an emerging treatment for various CRE infections.
Hakeam A. Hakeam, Hala Alsahli, Lama Albabtain, Shahad Alassaf, Zainab Al Duhailib, Sahar Althawadi   +5 more
doaj   +1 more source

Evaluation of ceftazidime/avibactam alone and in combination with amikacin, colistin and tigecycline against Klebsiella pneumoniae carbapenemase-producing K. pneumoniae by in vitro time-kill experiment.

PLoS ONE, 2021
Klebsiella pneumoniae carbapenemase-producing K. pneumoniae (KPC-Kp) poses a major threat to human health worldwide. Combination therapies of antibiotics with different mechanisms have been recommended in literatures.
Fangzhou Wang, Qian Zhou, Xiuwen Yang, Yan Bai, Junchang Cui   +4 more
doaj   +1 more source

In vitro activity of ceftazidime-avibactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa from sub-Saharan Africa: ATLAS Global Surveillance Program 2017–2021

Journal of Global Antimicrobial Resistance, 2023
: Objectives: To report the in vitro susceptibility of Enterobacterales (n = 3905) and Pseudomonas aeruginosa (n = 1,109) isolates, collected from patients in sub-Saharan Africa (four countries) in 2017–2021, to a panel of 10 antimicrobial agents with a
Mark G. Wise, James A. Karlowsky, Meredith A. Hackel, Mohamed Amine Harti, Bontle M.E. Ntshole, Eva Njeri Njagua, Rita Oladele, Catherine Samuel, Shameema Khan, Jeannette Wadula, Warren Lowman, Busisani W. Lembede, Daniel F. Sahm   +12 more
doaj   +1 more source

Clinical Efficacy of Ceftazidime-Avibactam in the Treatment of Infections Caused by Carbapenem–Resistant Gram-Negative Bacteria

Антибиотики и Химиотерапия, 2021
The wide spread of carbapenemases among gram-negative bacteria of the Enterobacterales order in hospitals around the world, including Russia, creates great difficulties in the effective use of antibiotics for these infections in the ICU.
S. V. Yakovlev
doaj   +1 more source